(Total Views: 828)
Posted On: 05/27/2020 5:12:57 AM
Post# of 148901
My CC summary:
A major concern of Dr. Pourhassan was to clarify the past mistakes of the previous CEO's who now want to go to court. Interim CFO Mulholland determine that they will have no impact on Cytodyn.
Cytodyn is moving forward on a broad front with 10 treatable implications in 2020 and receives confirmation from Dr. Lalezari, that some new cancer patients (round about 10) have been added to the treatment with Leronlimab. In this context, Leronlimab will also be used for compassionate use with FDA approval.
The broad front of 10 implications are to be achieved by a non-dilutive financing from a bank/investment bank via a loan and also to finance the NYSE listing.
Surprisingly, Dr. Pourhassan explained that CytoDyn is in discussion with 6 companies for oncology in discussion with 5 companies for Covid 19 and for HIV in discussion with 2 companies outside the USA.
While current talks are not business, they will certainly lead to future business and agreement on upfront payments and revenue. This brief statement about possible partnerships and agreements in my opinion means a very profitable future for Cytodyn, in one way or another.
The financing planned for the weekend and parallel listing on the NYSE or Nasdaq should be rewarded in the medium term by a higher share price, which in turn will result in much less dilution for the further financing through shares.
The complex Covid-19 documentation paper work for patient recruitment causes a certain time lag and has currently slowed down for a quick FDA approval for Emmergeny Use Application.
According to FDA and Dr. Pourhassan, the Compessionate Use could also delay the final FDA approval for the broad application of Covid-19.
The 1 million vials ordered from Samsung and AGT should be in stock by the end of June and beginning of July. This leads me to conclude and I suspect, that this is one of the reasons, why we are getting slightly delayed FDA approval - no approval without stocked vials!
Another important point is the nomination of a Pharma Manager to drive the business even more actively worldwide. It will be interesting to see from which stable of the big pharmaceutical industry he comes.
All in all everything sounds very positive and next week there could be some good news with the closing of the financing and the timeline for NYSE listing.
Partnerships in various countries with large pharmaceutical companies or pharmaceutical service providers are decorative accessories that should keep the course moving upward.
The most important thing is and remains the results of the study for Covid-19, which can be submitted to the FDA as an interim target for approval even after 50 treated patients as Dr. Pourhassan claimed!
Other Big Pharma companies would wish for such CEO's, at Cytodyn it is even the mandatory to get into the visible radar and attract further investors and partners!
All in my opinion and suggestion why the CC was important!
A major concern of Dr. Pourhassan was to clarify the past mistakes of the previous CEO's who now want to go to court. Interim CFO Mulholland determine that they will have no impact on Cytodyn.
Cytodyn is moving forward on a broad front with 10 treatable implications in 2020 and receives confirmation from Dr. Lalezari, that some new cancer patients (round about 10) have been added to the treatment with Leronlimab. In this context, Leronlimab will also be used for compassionate use with FDA approval.
The broad front of 10 implications are to be achieved by a non-dilutive financing from a bank/investment bank via a loan and also to finance the NYSE listing.
Surprisingly, Dr. Pourhassan explained that CytoDyn is in discussion with 6 companies for oncology in discussion with 5 companies for Covid 19 and for HIV in discussion with 2 companies outside the USA.
While current talks are not business, they will certainly lead to future business and agreement on upfront payments and revenue. This brief statement about possible partnerships and agreements in my opinion means a very profitable future for Cytodyn, in one way or another.
The financing planned for the weekend and parallel listing on the NYSE or Nasdaq should be rewarded in the medium term by a higher share price, which in turn will result in much less dilution for the further financing through shares.
The complex Covid-19 documentation paper work for patient recruitment causes a certain time lag and has currently slowed down for a quick FDA approval for Emmergeny Use Application.
According to FDA and Dr. Pourhassan, the Compessionate Use could also delay the final FDA approval for the broad application of Covid-19.
The 1 million vials ordered from Samsung and AGT should be in stock by the end of June and beginning of July. This leads me to conclude and I suspect, that this is one of the reasons, why we are getting slightly delayed FDA approval - no approval without stocked vials!
Another important point is the nomination of a Pharma Manager to drive the business even more actively worldwide. It will be interesting to see from which stable of the big pharmaceutical industry he comes.
All in all everything sounds very positive and next week there could be some good news with the closing of the financing and the timeline for NYSE listing.
Partnerships in various countries with large pharmaceutical companies or pharmaceutical service providers are decorative accessories that should keep the course moving upward.
The most important thing is and remains the results of the study for Covid-19, which can be submitted to the FDA as an interim target for approval even after 50 treated patients as Dr. Pourhassan claimed!
Other Big Pharma companies would wish for such CEO's, at Cytodyn it is even the mandatory to get into the visible radar and attract further investors and partners!
All in my opinion and suggestion why the CC was important!
(8)
(1)Scroll down for more posts ▼
